Customers in Europe reported false resistant Ceftriaxone results for Streptococcus anginosus and Streptococcus constellatus strains when using VITEK 2 AST-ST01 and AST-ST03 cards and VITEK 2 Systems Software 8.01 with EUCAST breakpoints. These false resistant results were reproduced internally by testing customer strains. A Ceftriaxone MIC overestimation was observed compared to the reference result. An internal study confirmed the performance of Streptococcus anginosus, Streptococcus constellatus, and Streptococcus intermedius had shifted for Ceftriaxone. With EUCAST Global European-based breakpoints, having no Intermediate MIC, this may constitute a category difference. Many strains demonstrated a result of MIC=1 (R) with EUCAST breakpoints, when an MIC=1 remains susceptible (S) for CLSI, Global CLSI-based and FDA breakpoints. The VITEK 2 Ceftriaxone test is included on all AST-ST cards intended for testing streptococci. All lots of AST-ST01, AST-ST02, and AST-ST03 are impacted and are distributed globally.